Roch Doliveux, the chief executive of Belgian pharmaceutical company UCB, has been appointed chairman of the Innovative Medicines Initiative’s governing board.
Doliveux is a veterinarian from France. He joined UCB in 2003 as director general of the pharma sector and became CEO in 2005. He is also a member of the board of Efpia, the European federation of pharmaceutical industries and associations.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.